CDMO News
Naobios to Scale Up Production of Sumagen’s HIV Vaccine Candidate by 2025
Naobios has reached a critical milestone in the production of an HIV-1 vaccine candidate for Korean-Canadian biotechnology firm Sumagen Canada Inc. The achievement marks the completion of bench-scale production of Sumagen’s SAV001 vaccine, a genetically modified, whole-killed HIV vaccine designed
30 October 2024